1White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein Ⅱ b/Ⅲ a Inhibitors (SYNERGY) trial. Am Heart J, 2006, 152: 1042-1050.
2Fox KA, Antman EM, Cohen M, et al. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention. Am J Cardiol, 2002, 90: 477-482.
3Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 ( ExTRACT-TIMI 25). Am Heart J, 2005,149 : 217-226.
4Ross AM, Molhoek P, LunderganC, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART Ⅱ). Circulation, 2001, 104:648-652.
5Sanchez-Pena P, Hulot JS, Urien S, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol, 2005, 60:364-373.
6Choussat R, Montalescot G, Collet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coil Cardiol, 2002, 40: 1943- 1950.
7Young JJ, Kereiakes DJ, Grines CL. et al. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol, 2000, 12 Suppl E:E14-18.
8Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med, 2006, 355 : 1006-1017.
9Kereiakes D, Kleiman N, Fry E. et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J, 2001,141:348-352.
10Natarajan MK, Velianou JL, Turpie AG, et al. A randomized pilot study of dalteparin versus unfractionated heparin during percutaneous coronary interventions. Am Heart J, 2006, 151:175.
6Rajan L,Moliterno DJ.Beyond Aspirin and Clopidogrel:Is there a need for additional antiplatelet therapy in ACS? Curr Cardiol Rep,2011,13:303-311.
7Eikelboom JW,Mehts SR,Anand SS,et al.Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.Circulation,2006,114:774-782.
8Rao SV,Jollis JG,Harrington RA,et al.Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.JAMA,2004,292:1555-1562.
9Rao SV,O'Grady K,Pieper KS,et al.Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes.Am J Cardiol,2005,96:1200-1206.
10Subherwal S,Bach RG,Chen AY,et al.Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction:the CRUSADE(Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines)Bleeding Score.Circulation,2009,119:1873-1 882.
